ABBV-2737 is a CFTR C2 corrector being studied for the treatment of cystic fibrosis (CF).

Type of Molecule

Small Molecule

Target

CTFR

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Cystic Fibrosis New Indication Phase 1